Litigation Details for Otsuka Pharmaceutical Co., Ltd. v. Sandoz Inc. (D. Del. 2019)
✉ Email this page to a colleague
Otsuka Pharmaceutical Co., Ltd. v. Sandoz Inc. (D. Del. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-11-01 |
| Court | District Court, D. Delaware | Date Terminated | 2022-08-31 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Defendant | Referred To | |
| Parties | H. LUNDBECK A/S; SANDOZ INC. | ||
| Patents | 10,307,419; 7,888,362; 8,349,840; 8,618,109; 9,839,637 | ||
| Attorneys | Erin M. Sommers; James B. Monroe | ||
| Firms | Young, Conaway, Stargatt & Taylor LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Otsuka Pharmaceutical Co., Ltd. v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Otsuka Pharmaceutical Co., Ltd. v. Sandoz Inc. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-03-16 | 11 | Answer to Complaint | U.S. Patent Nos. 7,888,362 (“’362 patent”), 8,349,840 (“’840 patent”), 8,618,109 (’109 patent”), 9,839,637… U.S. Patent Nos. 7,888,362 (“’362 patent”), 8,349,840 (“’840 patent”), 8,618,109 (“’109 patent”), 9,…civil action for patent infringement of U.S. Patent Nos. 7,888,362 (“the ’362 patent”), 8,349,840 (“the…the ’840 patent”), 8,618,109 (“the ’109 patent”), 9,839,637 (“the ’637 patent”), and 10,307,419 (“the …the ’419 patent”) (collectively, “patents in suit”), arising under the United States patent laws, Title | External link to document |
| 2020-09-30 | 18 | Status Report | of those patents, U.S. Patent No. 10,307,419 (“the ’419 patent”), is a formulation patent directed to…8,349,840; 8,618,109; 9,839,637 and 10,307,419 (“the ’419 patent”), which cover brexpiprazole, its use…allegations of patent infringement. Plaintiffs have asserted five patents-in-suit: U.S. Patent Nos. 7,888,362…other four patents. The ’419 patent expires over six years later than the other four patents. …This is an action for patent infringement of Otsuka Pharmaceutical Co., Ltd.’s patents covering REXULTI® | External link to document |
| 2019-11-01 | 4 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,888,362 ;8,349,840 ;8,618,109…2019 31 August 2022 1:19-cv-02080 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
